Breaking News

Synergy Completes Callisto Merger

January 18, 2013

Gains cancer therapeutics expertise

Synergy Pharmaceuticals, a drug developer focused on gastrointestinal disorders and diseases, has concluded its merger with Callisto Pharmaceuticals, a biotechnology company that develops novel therapeutics to treat cancer.
 
Under the terms of the merger agreement, each outstanding share of Callisto common stock was converted into one share of Synergy common stock and the approximately 22.3 million shares of Synergy held by Callisto were canceled. Callisto's common stock will no longer be traded on the OTC QB.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision